CL2018001452A1 - Composiciones anti-cgrp y uso de las mismas (divisional solicitud 201701379) - Google Patents

Composiciones anti-cgrp y uso de las mismas (divisional solicitud 201701379)

Info

Publication number
CL2018001452A1
CL2018001452A1 CL2018001452A CL2018001452A CL2018001452A1 CL 2018001452 A1 CL2018001452 A1 CL 2018001452A1 CL 2018001452 A CL2018001452 A CL 2018001452A CL 2018001452 A CL2018001452 A CL 2018001452A CL 2018001452 A1 CL2018001452 A1 CL 2018001452A1
Authority
CL
Chile
Prior art keywords
cgrp
antibodies
fragments
same
joint
Prior art date
Application number
CL2018001452A
Other languages
English (en)
Inventor
Brian Robert Kovacevich
Katie Olson
Maria-Cristina Loomis
Leon F Garcia-Martinez
Benjamin H Dutzar
John A Latham
Danielle M Mitchell
Nicole M Janson
Jens J Billgren
Patricia Dianne Mcneil
Original Assignee
Alderbio Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47175055&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2018001452(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alderbio Holdings Llc filed Critical Alderbio Holdings Llc
Publication of CL2018001452A1 publication Critical patent/CL2018001452A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCIÓN SE DIRIGE A ANTICUERPOS Y FRAGMENTOS DE LOS MIMOS QUE TIENEN ESPECIFICIDAD DE UNIÓN CON CGRP. OTRA REALIZACIÓN DE ESTA INVENCIÓN SE REFIERE A ANTICUERPOS DESCRITOS EN LA PRESENTE, Y FRAGMENTOS DE UNIÓN DE LOS MISMOS, QUE COMPRENDEN LAS SECUENCIAS DE LOS POLIPÉPTIDOS DE VH, VL Y CDR DESCRITOS EN LA PRESENTE Y LOS POLINUCLEÓTIDOS QUE LOS CODIFICAN. LA INVENCIÓN TAMBIÉN CONTEMPLA CONJUGADOS DE ANTICUERPOS ANTI-CGRP Y FRAGMENTOS DE UNIÓN DE LOS MISMOS CONJUGADOS CON UNO O MÁS RESTOS FUNCIONALES O DETECTABLES. LA INVENCIÓN CONTEMPLA ADEMÁS MÉTODOS PARA PRODUCIR DICHOS ANTICUERPOS ANTICGRP Y FRAGMENTOS DE UNIÓN DE LOS MISMOS. REALIZACIONES DE LA INVENCIÓN SE REFIEREN AL USO DE ANTICUERPOS ANTI-CGRP Y FRAGMENTOS DE UNIÓN DE LOS MISMOS PARA EL DIAGNÓSTICO, EVALUACIÓN Y TRATAMIENTO DE ENFERMEDADES O TRASTORNOS ASOCIADOS CON CGRP.
CL2018001452A 2011-05-20 2018-05-30 Composiciones anti-cgrp y uso de las mismas (divisional solicitud 201701379) CL2018001452A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161488660P 2011-05-20 2011-05-20

Publications (1)

Publication Number Publication Date
CL2018001452A1 true CL2018001452A1 (es) 2018-08-10

Family

ID=47175055

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2013003336A CL2013003336A1 (es) 2011-05-20 2013-11-20 Anticuerpo anti-cgrp humano; acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica y diagnostica que lo comprende; y su uso terapéutico
CL2017001379A CL2017001379A1 (es) 2011-05-20 2017-05-30 Composiciones anti-cgrp y uso de las mismas (solicitud divisional 3336-2013)
CL2018001452A CL2018001452A1 (es) 2011-05-20 2018-05-30 Composiciones anti-cgrp y uso de las mismas (divisional solicitud 201701379)

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CL2013003336A CL2013003336A1 (es) 2011-05-20 2013-11-20 Anticuerpo anti-cgrp humano; acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica y diagnostica que lo comprende; y su uso terapéutico
CL2017001379A CL2017001379A1 (es) 2011-05-20 2017-05-30 Composiciones anti-cgrp y uso de las mismas (solicitud divisional 3336-2013)

Country Status (35)

Country Link
US (10) US9745373B2 (es)
EP (5) EP3662932B1 (es)
JP (3) JP6282584B2 (es)
KR (1) KR102128627B1 (es)
CN (5) CN103748111B (es)
AP (1) AP2013007259A0 (es)
AR (3) AR086516A1 (es)
AU (3) AU2012258966C1 (es)
BR (2) BR122022012930B1 (es)
CA (3) CA3080000A1 (es)
CL (3) CL2013003336A1 (es)
CO (1) CO6870005A2 (es)
CY (2) CY1124209T1 (es)
DK (3) DK3495392T3 (es)
EA (3) EA031065B1 (es)
ES (3) ES2873837T3 (es)
FR (1) FR22C1032I2 (es)
HR (3) HRP20190640T1 (es)
HU (4) HUE054437T2 (es)
IL (4) IL229431B (es)
LT (4) LT3662932T (es)
MX (3) MX370749B (es)
NL (1) NL301181I2 (es)
NZ (1) NZ733060A (es)
PE (2) PE20141787A1 (es)
PH (1) PH12018500521A1 (es)
PL (3) PL3662932T3 (es)
PT (3) PT3495392T (es)
RS (3) RS58621B1 (es)
SG (2) SG10201604040PA (es)
SI (3) SI2710039T1 (es)
TR (1) TR201904088T4 (es)
TW (4) TWI646111B (es)
WO (1) WO2012162243A2 (es)
ZA (1) ZA201308637B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2008004467A0 (en) 2005-11-14 2008-06-30 Rinat Neurosciene Corp Antagonist antibodies directed against calcitonin generelated peptide anf methods using same
JP5537441B2 (ja) 2008-03-04 2014-07-02 ファイザー・リミテッド 慢性疼痛を治療する方法
HUE054437T2 (hu) * 2011-05-20 2021-09-28 H Lundbeck As Anti-CGRP készítmények és alkalmazásuk
EP2709663B1 (en) 2011-05-20 2019-03-20 AlderBio Holdings LLC Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
AU2012258976B8 (en) 2011-05-20 2017-07-20 H. Lundbeck A/S Use of anti-CGRP or anti-CGRP-R antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
TW201940691A (zh) 2013-03-15 2019-10-16 美商艾爾德生物製藥股份有限公司 抗體純化及純度監測
US20150017166A1 (en) * 2013-07-03 2015-01-15 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
JP6568099B2 (ja) 2014-03-21 2019-08-28 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
WO2016168757A1 (en) 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
EA201890578A1 (ru) * 2015-09-24 2018-12-28 Тева Фармасьютикалз Интернэшнл Гмбх Предотвращение, лечение и снижение (персистирующей) посттравматической головной боли
TW201725212A (zh) * 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
EP3408290A1 (en) * 2016-01-28 2018-12-05 Eli Lilly and Company Cgrp antibodies and uses thereof
CN108601833B (zh) 2016-02-01 2022-11-15 伊莱利利公司 甲状旁腺激素-抗rankl抗体融合化合物
JP7116685B2 (ja) 2016-04-15 2022-08-10 エイチ． ルンドベック アー／エス ヒト化抗ｐａｃａｐ抗体及びそれらの使用
CA3036632A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
CA3037661A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating cluster headache
US20190071490A1 (en) 2017-03-02 2019-03-07 Beth Israel Deaconess Medical Center, Inc. Preventing Post-Ictal Headaches
WO2018195361A2 (en) * 2017-04-19 2018-10-25 John Mansell Compositions and methods for treating pain disorders
JP7339262B2 (ja) 2018-01-12 2023-09-05 アムジェン インコーポレイテッド Ｐａｃ１抗体及びその使用
US11274158B2 (en) * 2018-01-30 2022-03-15 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators
WO2019165326A1 (en) * 2018-02-23 2019-08-29 REMD Biotherapeutics, Inc Calcitonin gene-related peptide (cgrp) antagonist antibodies
WO2019231800A1 (en) * 2018-05-31 2019-12-05 Eli Lilly And Company Anti-cgrp antibodies for treating menstrual-related migraines
US10899826B1 (en) * 2018-09-13 2021-01-26 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for an anti-CGRP antagonist antibody
EP3674418A1 (en) * 2018-12-26 2020-07-01 Life Length S.L. Method for measuring telomere associated variables and uses thereof for the diagnosis and/or prognosis of telomeric-associated diseases
EP3908606A4 (en) 2019-01-08 2022-11-23 H. Lundbeck A/S ACUTE AND RAPID TREATMENT OF HEADACHES USING ANTI-CGRP ANTIBODIES
JOP20210166A1 (ar) * 2019-01-08 2023-01-30 H Lundbeck As علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r
CA3168643A1 (en) * 2019-02-28 2020-09-03 Dandi Bioscience Inc. Polypeptide having antibacterial activity, composition for preventing or treating sepsis comprising same, and antibacterial composition
JOP20210247A1 (ar) * 2019-05-02 2023-01-30 H Lundbeck As علاج الصداع باستخدام أجسام مضادة لـ cgrp
WO2020239014A1 (zh) * 2019-05-30 2020-12-03 山东博安生物技术有限公司 抗cgrp抗体及其应用
AU2020202454A1 (en) 2020-04-06 2021-10-21 H. Lundbeck A/S Treatment of most bothersome symptom (MBS) associated with migraine using anti-CGRP antibodies
CA3212151A1 (en) 2021-03-02 2022-09-09 Cgrp Diagnostics Gmbh Treatment and/or reduction of occurrence of migraine
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine
EP4392447A1 (en) 2021-08-27 2024-07-03 H. Lundbeck A/S Treatment of cluster headache using anti-cgrp antibodies
WO2023161528A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN
CN117586390A (zh) * 2022-08-11 2024-02-23 上海君实生物医药科技股份有限公司 抗cgrp抗体及用途

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3662333A (en) 1970-09-08 1972-05-09 Bendix Corp Hydraulic accumulator charge detector and indicating system
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5123197A (ja) 1974-08-21 1976-02-24 Hitachi Ltd Purosesugasukuromatogurafuno ondoseigyohoshiki
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU570600B2 (en) * 1983-06-15 1988-03-17 Celltech Limited Peptides, pharmaceutical compositions,genes,vectors,host organisms, processes for there production and diagnostic reagents
JPS62129297A (ja) 1985-08-09 1987-06-11 Toyo Jozo Co Ltd カルシトニン遺伝子関連ペプチド誘導体
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US5364841A (en) 1988-01-11 1994-11-15 Amylin Pharmaceuticals, Inc. Treatment of obesity and essential hypertension and related disorders
US5266561A (en) 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
FR2669336B1 (fr) 1990-11-20 1993-01-22 Adir Nouveaux derives d'oxazolo pyridines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DE4227454C1 (de) * 1992-08-19 1994-02-03 Henning Berlin Gmbh Verfahren zur Früherkennung, zur Erkennung des Schweregrads sowie zur therapiebegleitenden Verlaufsbeurteilung einer Sepsis sowie Mittel zur Durchführung des Verfahrens
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
AU6445894A (en) 1993-03-19 1994-10-11 Duke University Method of treatment of tumors with an antibody binding to tenascin
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5436265A (en) 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5475995A (en) 1994-05-16 1995-12-19 Livingston; George G. Truck spare tire locking rod
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
ATE306930T1 (de) 1994-08-12 2005-11-15 Immunomedics Inc Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
WO1996005221A1 (en) 1994-08-16 1996-02-22 Human Genome Sciences, Inc. Calcitonin receptor
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5593994A (en) 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
FR2732221B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
US5510368A (en) 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5639780A (en) 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
EP0851759A4 (en) 1995-09-05 2000-12-06 Smithkline Beecham Corp COMPOUNDS AND RELATED METHODS
US5710024A (en) * 1996-07-23 1998-01-20 Smithkline Beecham Corporation Polynucleotides that encode the calcitonin gene-related peptide receptor coponent factor (HOUNDC44)
AU4261697A (en) 1996-09-09 1998-03-26 Smithkline Beecham Corporation Compounds and methods
CA2262818A1 (en) 1996-09-10 1998-03-19 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung Modified amino acids, pharmaceuticals containing these compounds and methods for their production
US6653104B2 (en) 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
WO1998056779A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation 4-sulfinyl benzamides as calcitonin gene-related peptide receptor antagonists
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
JP2002525371A (ja) 1998-09-30 2002-08-13 メルク シャープ エンド ドーム リミテッド Ｃｇｒｐリガンドとしてのベンゾイミダゾリニルピペリジン
WO2000023579A1 (en) 1998-10-22 2000-04-27 The Regents Of The University Of California Functionally assembled antigen-specific intact recombinant antibody and a method for production thereof
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1031350A1 (en) 1999-02-23 2000-08-30 Warner-Lambert Company Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
US6313097B1 (en) 1999-03-02 2001-11-06 Boehringer Ingelheim Pharma Kg Antagonists of calcitonin gene-related peptide
US6521609B1 (en) 1999-08-10 2003-02-18 Boehringer Ingelheim Pharma Kg Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes
MXPA02003108A (es) 1999-09-25 2003-10-14 Univ Iowa Res Found Acidos nucleicos inmunoestimuladores.
CA2401652A1 (en) 2000-03-01 2001-09-07 Medimmune, Inc. High potency recombinant antibodies and method for producing them
US6406863B1 (en) 2000-06-23 2002-06-18 Genetastix Corporation High throughput generation and screening of fully human antibody repertoire in yeast
US20020162125A1 (en) 2001-03-06 2002-10-31 Anne-Marie Salmon Methods and compositions for the modulation of neurogenic inflammatory pain and physical opiate withdrawal
US20030181462A1 (en) 2001-08-17 2003-09-25 Boehringer Ingelheim Pharma Kg Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine
EP1461068A4 (en) 2001-11-26 2006-03-29 Protemix Corp Ltd METHOD AND COMPOSITIONS FOR NORMALIZING LIPID MIRRORS IN MIRACLE TISSUE
MXPA04009418A (es) 2002-03-29 2005-06-08 Schering Corp Anticuerpos monoclonales humanos par interleucina-5, y metodos y composiciones que comprenden los mismos.
US7879991B2 (en) 2002-05-06 2011-02-01 Noxxon Pharma Ag CGRP binding nucleic acids
US20040110170A1 (en) 2002-05-18 2004-06-10 The Regents Of The University Of California Cloning and characterization of calcitonin gene related peptide receptors
US7345065B2 (en) 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
US20040063735A1 (en) 2002-06-05 2004-04-01 Chaturvedula Prasad V. Calcitonin gene related peptide receptor antagonists
DE60305919T2 (de) 2002-06-28 2007-01-18 Domantis Limited, Cambridge Dual-specifische liganden mit erhöhter halbwertszeit
CN1674919A (zh) 2002-08-12 2005-09-28 比克尔·斯韦恩森 Cgrp拮抗剂化合物在治疗牛皮癣中的应用
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
DE10250082A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
WO2004050683A2 (en) 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to tumor necrosis factor and uses thereof
KR101250818B1 (ko) 2002-12-24 2013-04-15 리나트 뉴로사이언스 코프. 항-ｎｇｆ 항체 및 그것을 이용하는 방법
US7205293B2 (en) 2003-03-14 2007-04-17 Merck & Co., Inc. Benodiazepine spirohydantoin CGRP receptor antagonists
AU2004222383B2 (en) 2003-03-14 2009-10-01 Merck Sharp & Dohme Corp. Bicyclic anilide spirohydantoin CGRP receptor antagonists
AU2004222328B2 (en) 2003-03-14 2009-10-08 Merck Sharp & Dohme Corp. Aryl spirohydantoin CGRP receptor antagonists
US7192954B2 (en) 2003-03-14 2007-03-20 Merck & Co., Inc. Monocyclic anilide spirohydantoin CGRP receptor antagonists
AU2004222378B2 (en) 2003-03-14 2008-08-14 Merck Sharp & Dohme Corp. Carboxamide spirohydantoin CGRP receptor antagonists
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
JP4705908B2 (ja) 2003-04-15 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｃｇｒｐ受容体拮抗薬
WO2004097421A2 (en) 2003-04-29 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
CA2532064A1 (en) 2003-07-15 2005-02-03 Merck & Co., Inc. Hydroxypyridine cgrp receptor antagonists
CN1871359B (zh) * 2003-10-22 2010-11-17 凯克研究生院 使用单倍体交配策略在酵母中合成异聚多亚基多肽的方法
US20080070239A1 (en) 2003-10-29 2008-03-20 University Of Rochester Detection of neureopeptides associated with pelvic pain disorders and uses thereof
CA2552757A1 (en) 2004-01-13 2005-08-04 Vasogenix Pharmaceuticals, Inc. Methods of using cgrp for cardiovascular and renal indications
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004018794A1 (de) 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7279471B2 (en) 2004-04-15 2007-10-09 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
TWI432196B (zh) 2005-01-18 2014-04-01 Euro Celtique Sa 內臟痛的治療
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
CA2619856A1 (en) 2005-08-25 2007-03-01 Wex Pharmaceuticals Inc. Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
AP2008004467A0 (en) 2005-11-14 2008-06-30 Rinat Neurosciene Corp Antagonist antibodies directed against calcitonin generelated peptide anf methods using same
US20070108378A1 (en) 2005-11-14 2007-05-17 Toru Terabayashi High pressure optical cell for a downhole optical fluid analyzer
US8071770B2 (en) 2005-11-18 2011-12-06 Merck Sharp & Dohme Corp. Spirohydantoin aryl CGRP receptor antagonists
WO2007076336A1 (en) 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
US9074352B2 (en) 2006-03-27 2015-07-07 John R. Ramun Universal control scheme for mobile hydraulic equipment and method for achieving the same
DK2021463T3 (en) 2006-05-19 2017-01-16 Alder Biopharmaceuticals Inc Culture method to obtain a cloned population of antigen-specific B cells
WO2007141285A1 (en) 2006-06-08 2007-12-13 Boehringer Ingelheim International Gmbh Treatment of gastrointestinal disorders with cgrp-antagonists
JP5511379B2 (ja) 2006-07-21 2014-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｇｒｐレセプターアンタゴニスト
US8075902B2 (en) * 2007-01-03 2011-12-13 Michael Powell Diagnosis and treatment of cancer related to human dormancy
NZ601583A (en) 2007-05-21 2013-08-30 Bristol Myers Squibb Co Novel rabbit antibody humanization methods and humanized rabbit antibodies
WO2008144753A2 (en) 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Antibodies to tnf alpha and use thereof
CA2688146C (en) 2007-05-21 2018-03-06 Alder Biopharmaceuticals, Inc. Antibodies to il-6 and use thereof
GB0725103D0 (en) * 2007-12-21 2008-01-30 Glaxo Group Ltd Novel compounds
JP5537441B2 (ja) * 2008-03-04 2014-07-02 ファイザー・リミテッド 慢性疼痛を治療する方法
RU2467765C2 (ru) * 2008-03-04 2012-11-27 Пфайзер Лимитед Способы лечения воспалительной боли
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
MX2012002464A (es) 2009-08-28 2012-03-14 Rinat Neuroscience Corp El uso de anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de la calcitonina para tratar dolor visceral.
JO3330B1 (ar) 2010-06-10 2019-03-13 Lilly Co Eli الأجسام المضادة cgrp
US11214610B2 (en) * 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
HUE054437T2 (hu) * 2011-05-20 2021-09-28 H Lundbeck As Anti-CGRP készítmények és alkalmazásuk
AU2012258976B8 (en) 2011-05-20 2017-07-20 H. Lundbeck A/S Use of anti-CGRP or anti-CGRP-R antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
EP2709663B1 (en) 2011-05-20 2019-03-20 AlderBio Holdings LLC Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
EA201890578A1 (ru) 2015-09-24 2018-12-28 Тева Фармасьютикалз Интернэшнл Гмбх Предотвращение, лечение и снижение (персистирующей) посттравматической головной боли
US20190071490A1 (en) * 2017-03-02 2019-03-07 Beth Israel Deaconess Medical Center, Inc. Preventing Post-Ictal Headaches
US11752099B2 (en) * 2017-03-27 2023-09-12 W. L. Gore & Associates, Inc. Injectable and biodegradable polymer formulations for controlled release of bioactive agents
US11400136B2 (en) * 2017-06-19 2022-08-02 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection
TWI754772B (zh) * 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
JOP20210166A1 (ar) 2019-01-08 2023-01-30 H Lundbeck As علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r
EP3908606A4 (en) * 2019-01-08 2022-11-23 H. Lundbeck A/S ACUTE AND RAPID TREATMENT OF HEADACHES USING ANTI-CGRP ANTIBODIES

Also Published As

Publication number Publication date
PL3662932T3 (pl) 2021-09-06
CL2013003336A1 (es) 2014-06-06
ES2893073T3 (es) 2022-02-07
ES2715001T3 (es) 2019-05-31
AU2012258966B2 (en) 2017-03-09
SI3662932T1 (sl) 2021-08-31
TW201811835A (zh) 2018-04-01
IL270382B (en) 2020-11-30
TWI692485B (zh) 2020-05-01
PH12018500521A1 (en) 2019-04-15
LTPA2022511I1 (es) 2022-07-11
AU2017203890B2 (en) 2019-06-06
SG10201604040PA (en) 2016-07-28
NZ733060A (en) 2022-08-26
MX2019008185A (es) 2019-09-09
EP3662932A1 (en) 2020-06-10
IL261927B (en) 2019-11-28
EP3495392B1 (en) 2021-08-18
AR118605A2 (es) 2021-10-20
HUS2200031I1 (hu) 2022-07-28
AR086516A1 (es) 2013-12-18
US20190092842A1 (en) 2019-03-28
US20180215816A1 (en) 2018-08-02
TWI719869B (zh) 2021-02-21
AR123876A2 (es) 2023-01-18
CN108424452A (zh) 2018-08-21
TW202033559A (zh) 2020-09-16
WO2012162243A3 (en) 2013-01-17
EP4115905A1 (en) 2023-01-11
CN108373502B (zh) 2022-03-22
NZ618637A (en) 2016-03-31
NL301181I2 (nl) 2022-11-24
TW201936642A (zh) 2019-09-16
DK2710039T3 (en) 2019-04-01
US20210047391A1 (en) 2021-02-18
CA2836649A1 (en) 2012-11-29
AU2012258966C1 (en) 2022-02-03
NZ717570A (en) 2018-09-28
IL229431B (en) 2018-10-31
MX2019015745A (es) 2020-02-13
JP6952736B2 (ja) 2021-10-20
JP2014517699A (ja) 2014-07-24
EP3662932B1 (en) 2021-04-07
LT3495392T (lt) 2021-09-27
EP2710039A4 (en) 2014-11-19
AU2019226231B2 (en) 2021-06-03
WO2012162243A2 (en) 2012-11-29
US10189895B2 (en) 2019-01-29
CN107586338B (zh) 2021-09-17
EA039905B1 (ru) 2022-03-25
US10208112B2 (en) 2019-02-19
CN103748111A (zh) 2014-04-23
US10533048B2 (en) 2020-01-14
PT2710039T (pt) 2019-04-23
EA201301295A1 (ru) 2014-04-30
EA201891284A1 (ru) 2018-11-30
FR22C1032I2 (fr) 2023-06-02
US10214582B2 (en) 2019-02-26
HRP20210777T1 (hr) 2021-06-25
CN108373502A (zh) 2018-08-07
CN107586338A (zh) 2018-01-16
TW201300419A (zh) 2013-01-01
SG194938A1 (en) 2013-12-30
EP2710039A2 (en) 2014-03-26
US20240174738A1 (en) 2024-05-30
US9745373B2 (en) 2017-08-29
CN107602700A (zh) 2018-01-19
IL268464B (en) 2020-10-29
CN107602700B (zh) 2021-12-17
JP2019150044A (ja) 2019-09-12
MX2013013535A (es) 2015-08-20
IL268464A (en) 2019-09-26
PE20180502A1 (es) 2018-03-09
US20190211085A1 (en) 2019-07-11
EP2710039B1 (en) 2019-01-09
CA3080000A1 (en) 2012-11-29
IL261927A (en) 2018-10-31
RS62306B1 (sr) 2021-09-30
NL301181I1 (es) 2022-06-15
KR102128627B1 (ko) 2020-06-30
PT3495392T (pt) 2021-09-22
US20170174754A1 (en) 2017-06-22
US20180215814A1 (en) 2018-08-02
MX370749B (es) 2019-12-20
US11111289B2 (en) 2021-09-07
PT3662932T (pt) 2021-05-14
CY1124209T1 (el) 2022-05-27
HRP20211395T1 (hr) 2021-12-10
EP3875115A1 (en) 2021-09-08
SI2710039T1 (sl) 2019-05-31
AU2019226231A1 (en) 2019-09-26
BR112013029932A2 (pt) 2017-01-31
HUE054437T2 (hu) 2021-09-28
JP2018038391A (ja) 2018-03-15
RS58621B1 (sr) 2019-05-31
JP6282584B2 (ja) 2018-02-21
CA3079978A1 (en) 2012-11-29
LT3662932T (lt) 2021-06-10
CA2836649C (en) 2020-06-23
CO6870005A2 (es) 2014-02-20
KR20140042819A (ko) 2014-04-07
TWI685505B (zh) 2020-02-21
EA201592042A1 (ru) 2016-03-31
AP2013007259A0 (en) 2013-11-30
US20180215813A1 (en) 2018-08-02
LT2710039T (lt) 2019-04-25
PL3495392T3 (pl) 2021-12-13
EP3495392A1 (en) 2019-06-12
DK3662932T3 (da) 2021-05-17
CY1124515T1 (el) 2022-07-22
CN103748111B (zh) 2018-04-27
RS61793B1 (sr) 2021-06-30
BR122022012930B1 (pt) 2023-10-10
JP6527563B2 (ja) 2019-06-05
ZA201308637B (en) 2022-11-30
US20120294797A1 (en) 2012-11-22
PE20141787A1 (es) 2014-12-07
US20180215815A1 (en) 2018-08-02
DK3495392T3 (da) 2021-09-13
HUE044062T2 (hu) 2019-09-30
HRP20190640T1 (hr) 2019-05-31
US10066009B2 (en) 2018-09-04
TR201904088T4 (tr) 2019-05-21
FR22C1032I1 (fr) 2022-09-09
IL229431A0 (en) 2014-01-30
ES2873837T3 (es) 2021-11-04
AU2017203890A1 (en) 2017-06-29
TWI646111B (zh) 2019-01-01
CL2017001379A1 (es) 2017-12-29
US10179809B2 (en) 2019-01-15
HUE055505T2 (hu) 2021-11-29
CN108424452B (zh) 2021-08-03
EA031065B1 (ru) 2018-11-30
SI3495392T1 (sl) 2021-11-30
PL2710039T3 (pl) 2019-07-31

Similar Documents

Publication Publication Date Title
CL2018001452A1 (es) Composiciones anti-cgrp y uso de las mismas (divisional solicitud 201701379)
CY1120414T1 (el) Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους
AR092005A1 (es) Anticuerpos anti-pcsk9 y uso de los mismos
BR112012024713A2 (pt) "anticorpo humanizado, anticorpo monoclonal humanizado ou fragmento de anticorpo, seus usos, polinucleotídeo isolado, e composição farmacêutica"
HN2011001210A (es) Anticuerpos humanos de alta afinidad para el receptor il-4 humano
ECSP099656A (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes
AR095556A1 (es) Anticuerpos contra hgf y composiciones que contienen a los mismos
AR074360A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
AR080795A1 (es) Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
MY186351A (en) Multispecific antibodies
AR071547A1 (es) Anticuerpos biespecificos bivalentes
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
BRPI0809989B8 (pt) usos de um anticorpo ou fragmento de ligação a antígeno do mesmo que se liga a isoforma extradomínio-a (ed-a) de fibronectina e/ou ao ed-a de fibronectina
AU2011336470A8 (en) Anti-NGF compositions and use thereof
BR112014008382A2 (pt) anticorpo especificamente ligando a epítope no domínio sema do c-met
CR10736A (es) Composiciones y metodos relacionados con los anticuerpos del receptor del glucagon
AR059809A1 (es) Anticuerpos anti-5t4 y sus usos
GT200900167A (es) Anticuerpos humanos contra el ligando 4 de tipo delta humano.
BR112013020500A2 (pt) anticorpo isolado, recombinante ou purificado
AR073232A1 (es) Anticuerpos anti-il-17a/f biespecificos y con reactividad cruzada
PE20091520A1 (es) Anticuerpos bivalentes biespecificos
AR070346A1 (es) Anticuerpo especifico del receptor de linfopoyetina estromal timica (tslpr) y usos en trastornos inflamatorios e inflamatorios alergicos
BR112014015111A2 (pt) composições e processos para anticorpos que se direcionam ao fator p
PE20141659A1 (es) Dominios variables singulares anti-vgf fusionados con dominios de fc
PE20130207A1 (es) Anticuerpos antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones